Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CELC · against 305 other Healthcare companies of similar size
Ranked #232 of 306 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score75 peers with a valuation score of 0–9, including CELC · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | CELC | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 302 reported | -6.2% | 2.5% | 17% | 30% | |
| EBITDA yieldHigher is better · 300 reported | -6.1% | 4.8% | 13% | 50% | |
| Free cash flow yieldHigher is better · 157 reported | -5.6% | 0.6% | 24% | 20% | |
| Book yieldHigher is better · 300 reported | -0.4% | 28.9% | 2% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 232 | 2.9B USD | 8 | 44 | |
| 232 | 2.2B USD | 8 | 32 | |
| 232 | 2.7B USD | 8 | 50 | |
| 232 | 2.4B USD | 8 | 6 | |
| 232 | 3.4B USD | 8 | 17 | |
| 232 | 5.7B USD | 8 | 52 | |
| 232 | 2.3B USD | 8 | 25 | |
| 232 | 5.4B USD | 8 | 38 | |
| 232 | 4.8B USD | 8 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score